In this prospective cohort of treatment-naïve advanced lung adenocarcinoma, the T790M mutation was found in only 0.4% of our Chinese patients using the ARMS assay, accounting for 0.8% of EGFR M+ patients, all of which were observed concomitantly with the EGFR L858R mutation. This evidence concerns the gene EGFR and lung adenocarcinoma.